BURLINGAME, California – Feb 20, 2025
Accelerating Innovation with AI-Powered Drug Design
Incyte (Nasdaq: INCY) and Genesis Therapeutics have entered into a strategic AI-focused collaboration to drive the discovery and development of novel small molecule therapeutics. Leveraging Genesis’ GEMS platform (Genesis Exploration of Molecular Space), the partnership aims to identify and optimize drug candidates for targets selected by Incyte, with the potential to accelerate breakthroughs in areas of high unmet medical need.
Harnessing Generative AI to Unlock Challenging Targets
Traditional drug discovery often struggles with complex targets due to limited data and slow optimization cycles. Genesis’ GEMS AI platform integrates generative models, diffusion techniques, and physics-based simulations to rapidly design and refine molecules.
“As a leader in pharmaceutical innovation, Incyte is continually seeking transformative technologies,” said Pablo J. Cagnoni, M.D., President and Head of R&D at Incyte. “This collaboration with Genesis enables us to harness cutting-edge AI to accelerate the discovery of breakthrough small molecule therapies.”
Strategic and Financial Terms
- Genesis receives a $30 million upfront payment for collaboration on two initial drug targets.
- Incyte holds exclusive rights to develop and commercialize resulting therapeutics.
- Incyte may nominate an additional target for a predetermined fee.
- Genesis is eligible for up to $295 million per target in development, regulatory, and commercial milestone payments, plus tiered royalties on future product sales.
Reshaping the Future of AI-Driven Drug Discovery
This collaboration underscores the growing role of artificial intelligence in redefining pharmaceutical R&D. By combining Incyte’s deep expertise in drug development with Genesis’ cutting-edge AI capabilities, the companies aim to accelerate the journey from molecular discovery to clinical success—ultimately bringing life-changing therapies to patients faster.
About Genesis Therapeutics
Genesis Therapeutics is an AI-driven biotech company using its GEMS platform to design and optimize small molecule therapeutics for complex targets. Combining advanced AI, machine learning, and experimental validation, Genesis accelerates drug discovery from its headquarters in Burlingame, CA, and San Diego lab. Backed by $300M+ in funding, it is building a pipeline of breakthrough therapies.
By
